Kavindra Nath, PhD

Call 800-789-7366
Headshot of Kavindra Nath, PhD
Penn Medicine Provider

About me

  • Research Associate Professor of Radiology

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
Dr. Nath is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Wang S, Lobello C, Gupta P, Francis R, Vistarop A, Shah B, Zamora-Erazo S, F Ahmed, Rushmore D, Kalgren A, Nelson D, Dupoux V, Basappa J, Baldwin D, Fung H, Jillab M, Lee H, Cai KQ, Nejati R, Boldajipour B, Franco-Barazza, J, Lee G, Nath K, Wasik MA. Multipronged enhancement of CART-cell activity against ROR1 neoantigen by inhibition of H3K27 methyltransferase EZH2 , Cell Rep Med. : 2026

Basappa J, Goldman AR, Lobello C, Wang S, Rushmore D, Melnikov O, Sen NV, Mallikarjuna VS, Jain P, Edalati M, Nelson DS, Cai KQ, Lu P, Nejati R, Borghaei H, Gupta PK, Nath K, Wellen KE, Wasik MA Mitochondrial ACSS1 links acetate metabolism to pyrimidine biosynthesis in nutrient-stressed B-cell lymphomas , Cancer Lett.: 2026

*Nath K, Gupta PK, Wang S, Shestov AA, Sen N, Rao S, Orlovskiy S, Lobello C, Rushmore D, Arias-Mendoza F, Basappa J, Nelson DS, *Wasik MA Magnetic resonance spectroscopy–based detection of response to therapy targeting glutaminolysis in lymphoma , Blood Neoplasia: 2025

Gupta PK, Li LZ, Singh DK, Nova S, Arias-Mendoza F, Orlovskiy S, Chawla S, Nelson DS, Farwell MD, Nath K* MRS and Optical Imaging Studies of Therapeutic Response to Combination Therapy Targeting BRAF/MEK in Murine Melanomas , Acad Radiol : 2026 May;33(5):1793-1802 *Corresponding Author

Orlovskiy S, Gupta PK, Arias-Mendoza F, Singh DK, Nova S, Nelson DS, Narayan V, Koch CJ, Hardy M, You M, Kalyanaraman B, Nath K* Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A (1)H and (31)P Magnetic Resonance Spectroscopy Study , Int J Mol Sci.: 2025

Gupta PK*, Orlovskiy S, Arias-Mendoza F, Nelson DS, Nath K* 1H and 31P Magnetic Resonance Spectroscopic Metabolomic Imaging: Assessing Mitogen-Activated Protein Kinase Inhibition in Melanoma , Cells, 13(14): 2024 *Corresponding Author,1220

*Nath K, Gupta PK, Basappa J, Wang S, Sen N, Lobello C, Tomar JS, Shestov AA, Orlovskiy S, Arias-Mendoza F, Rauert-Wunderlich H, Nelson DS, Glickson JD, *Wasik MA Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition , J Transl Med. , 22(1): 2024 *Corresponding Author,622

Orlovskiy S, Gupta PK, Roman J, Arias-Mendoza F, Nelson DS, Koch CJ, Narayan V, Putt ME and Nath K* Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy , Cancers, 16(1384): 2024 *Corresponding Author

Gupta PK, Orlovskiy S, Arias-Mendoza F, Nelson DS, Osborne A, Pickup S, Glickson JD, Nath K* Metabolic Imaging Biomarkers of Response to Signaling Inhibition Therapy in Melanoma , Cancers, 16: 2024 *Corresponding Author, 365

Gupta PK, Orlovskiy S, Roman J, Pickup S, Nelson DS, Glickson JD, Nath K* pH-dependent structural characteristics of lonidamine: (1)H and (13)C NMR study , RSC Adv, 13(29): 2023. *Corresponding Author,19813-19816